By 5 years of age, 90-95% of children are nearly completely continent during the day, and 80-85% are continent at night. Subsequently, 15% of children recover every year. However, approximately 0.5% of children carry over the disorder into their adulthood 1) . Nocturnal enuresis refers to the occurrence of involuntary voiding at night after 5 years old, the age when volitional control of micturition is expected. Enuresis may be primary (estimated 75-90% of children with enuresis; nocturnal urinary control never achieved) or secondary (10-25%; the child was dry at night for at least a few months and then enuresis developed). Nocturnal enuresis is a heterogeneous condition that includes a spectrum of disorders with different underlying pathophysiological mechanisms 2) . Current evidence suggests that the major pathogenic factors involved in nocturnal enuresis are nocturnal polyuria, small bladder capacity and/or detrusor overactivity, and a high arousal threshold
2)-4)
. Enuresis is divided into monosymptomatic and non-monosymptomatic forms.
Monosymptomatic enuresis is defined as enuresis in children without any other lower urinary tract symptoms and without a history of bladder dysfunction 2) .
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Non-monosymptomatic enuresis is defined as enuresis in children with other lower urinary tract symptoms, including 1) consistently increased (≥8 times/day) or decreased (≤3 times/day) voiding frequency, 2) daytime incontinence, 3) urgency, 4) hesitancy (difficulty initiating voiding), 5) straining (application of abdominal pressure to initiate and maintain voiding), 6) a weak stream, 7) intermittency (micturition occurs in several discrete spurts), 8) holding maneuvers (strategies used to postpone voiding), 9) a feeling of incomplete emptying, 10) post-micturition dribble, and 11) genital or lower urinary tract pain 2) .
Pretreatment evaluation
Thorough history taking including the presence of 11 symptoms described above is an essential component for detecting underlying bladder dysfunction. In addition, it is important to look for causes of nocturnal enuresis that may require additional evaluation and treatment (eg, diabetes mellitus, obstructive sleep apnea, encopresis or constipation, bowel and bladder dysfunction, etc). It is difficult to successfully treat enuresis if coexistent constipation is not addressed. When evaluating for constipation, it may be helpful to ask about soiling in addition to the usual questions about bowel habits. A brief but thorough physical examination also should be performed primarily to identify rare underlying anatomical (phimosis and labial agglutination) or neurogenic (spinal malfunction) causes.
Management approach
Management of nocturnal enuresis may involve one or a combination of interventions, including, 1) education and advice (given the high rate of spontaneous resolution), 2) motivational therapy (eg, sticker or star chart), and 3) active therapy (desmopressin and enuresis alarms).
Education and advice
The education and advice typically includes the following information: 1) Enuresis resolves on its own in the majority of children. 2) Enuresis is the fault of neither the child nor the caregivers; children should not be punished for bedwetting. 3) The child should attempt to void regularly during the day and just before going to bed (a total of four to seven times); if the child wakes at night, the caregivers should take him/her to the toilet. 4) High-sugar and caffeine-based drinks should be avoided in children with enuresis, particularly in the evening hours. 5) Daily fluid intake should be concentrated in the morning and early afternoon; fluid and solute intake should be minimized during the evening. 6) Keeping a calendar of wet and dry nights helps to determine the effect of interventions.
Motivational therapy
Once the child agrees to accept some responsibility for the treatment program, he or she can be motivated by keeping a record of progress. Initial rewards should be given for agreed-upon behavior (eg, going to the toilet before bedtime) rather than dryness. Successively larger rewards, agreed upon in advance, are given for longer compliance with agreed-upon behavior and, eventually, for longer periods of dryness (eg, a sticker on a calendar for each dry night, a book for seven consecutive dry nights). Penalties (ie, removal of previously gained rewards) are counterproductive. Motivational therapy is a good first-line therapy for nocturnal enuresis in younger children who do not wet the bed every night. Motivational therapy is estimated to be successful (14 consecutive dry nights) in 25 percent of children and to lead to significant improvement (decrease in enuretic events by ≥80 percent) in more than 70 percent 5) . If motivational therapy fails to lead to improvement after one month, the addition of active interventions may be warranted.
Addition of active therapy
Enuresis alarms and desmopressin are effective active therapies for nocturnal enuresis 6) .
1) Enuresis alarms
Enuresis alarms are activated when a sensor, placed in the undergarments, detects moisture; the arousal devise is usually an auditory alarm and/or a vibrating pager. The alarms work through condi-tioning: the child learns to wake or inhibit bladder contraction in response to the physiologic conditions present before wetting. Enuresis alarms work best for well-motivated families and children with frequent enuresis (more than twice per week). Enuresis alarms are the most effective means of controlling nocturnal enuresis and preventing relapse 7) . In a meta-analysis of 56 randomized trials (3257 children), 66 percent of children became dry for 14 consecutive nights during alarm use versus only 4 percent of no-treatment controls ( , however, alternative interventions may be warranted if there has been no improvement after 6-8 weeks of alarm therapy 8) .
2) Desmopressin treatment Desmopressin (a synthetic vasopressin analog) is a first-line treatment for enuresis in children older than five years whose bedwetting has not responded to advice about fluid intake, toileting, or an appropriate reward system. It is an alternative to enuresis alarms for children and families who seek rapid or short-term improvement of enuresis; have failed, refused, or are unlikely to adhere to enuresis alarm treatment; and for whom an enuresis alarm is unsuitable. Desmopressin works best for children with nocturnal polyuria and normal functional bladder capacity. Nocturnal polyuria is defined 2) by nocturnal urine production greater than 130 percent of expected bladder capacity for age which is estimated with the following formula: 30 x (age [in years] + 1) 2) . Approximately 30 percent of patients achieve total dryness using desmopressin, with perhaps another 40 percent exhibiting a significant decrease in nighttime wetting 10) . Regularly, oral melt tablets are given 30 to 60 minutes before bedtime. The initial dose is 120 mcg; if needed after 10 to 14 days, the dose may be increased by 120 mcg to a maximum dose of 240 mcg 10) . If effective, it should be used for 3-6 months, and then an attempt should be made to taper the dosage.
Treatment options for the refractory patients

Anticholinergics
For therapy-resistant enuresis or children with symptoms of an overactive bladder, anticholinergic therapy is indicated. Oxybutynin 5 mg or tolterodine 2 mg at bedtime often are prescribed. If the medication is ineffective, the dosage may be doubled. The clinician should monitor for constipation as a potential side effect.
Tricyclic antidepressants
Another option is imipramine, which is a tricyclic antidepressant. This medication has mild anticholinergic and α-adrenergic effects, reduces urine output slightly, and also might alter the sleep pattern. The dosage of imipramine is 10-25 mg. Reported success rates are 30-60%. Side effects include anxiety, insomnia, and dry mouth, and heart rhythm may be affected. If there is any history of palpitations or syncope in the child, or sudden cardiac death or unstable arrhythmia in the family, long QT syndrome in the patient needs to be excluded. The use of tricyclic antidepressants seemed common in Japan previously, however, since they are potentially cardiotoxic and an overdose may prove fatal 10) , the cautious use of them is warranted in Europe and United States 8) .
Yokukansan as an alternative therapy for nocturnal enuresis
Sleep and nocturnal enuresis
Many enuretic children are difficult to wake up 11) and indicate elevated arousal thresholds 12)
. Although children with enuresis are generally believed to have sleep that is too deep with decreased arousability, Yeung CK et al.
13) recently
showed the evidence of disturbed superficial sleep rather than too deep sleep in enuretic patients. In their study polysomnography and continuous cystometry showed interaction between bladder overactivity and cortical arousability. Enuretic children had more light sleep associated with frequent cortical arousals but an inability to awaken completely. Dhondt K et al. provided additional evidence of increasing arousability in children with refractory nocturnal enuresis 14) . They showed that a high incidence of periodic limb movement (exten- sions of the big toe and dorsiflexions of the ankle with occasional flexions of the knee and hip occurring repetitively) during sleep in their patients, suggesting that they have disrupted sleep architecture. Cohen-Zrubavel V, et al. 15) studied the sleep state of enuretic patients using actigraph, a wristwatch-like device that can be worn by the child for an extended period and can monitor sleep-wake patterns in the childʼs natural sleep environment. The compromised sleep patterns of enuretic patients were reflected in a higher number of actigraphic nighttime awakenings, the reduced percentages of motionless sleep, the higher number of reported nighttime awakening, and the increased sleep latency.
Yokukansan administration 1) Overview
Yokukansan (Tsumura TJ-54) has been approved in Japan to treat patients with nervousness, insomnia, and night terrors and temper tantrums in children 16) , however, the precise pharmacological mechanisms by which yokukansan improves the various pathological condition remained unsolved. Recent experimental investigations showed that yokukansan is a partial dopamine D2 agonist, 5-HT (5-hydroxytryptamine) 1A agonist, and 5-HT2A antagonist 17) , and it might modulate the state of sleep. With the regard of sleep and wakefulness, the following findings might be taken into consideration:
(1) Experiments with rats showed, under conditions of low arousal, the D2 agonist quinpirole promotes wakefulness after an intracerebroventricular administration 18) , (2) Systemic administration of 5-HT1A receptor agonist flesinoxan (8-OH-DPAT; 8-hydroxy-2-(di-n-propylamino)tetralin) increases wakefulness in rats 19) , and (3) 5-HT2A antagonists (volinanserin, pruvanserin) increases slow wave sleep 20) 21) .
2) Our clinical experience We have recently experienced yokukansan treatment for monosymptomatic nocturnal enuresis 22) . Without satisfactory outcomes after the motivational therapy, we started oral desmopressin in 32 patients with monosymptomatic nocturnal enuresis. At 4 and 8 weeks following initiation of desmopressin, the response in each child was assessed on the basis set forth by the standardization committee of . The sum of scores provides a total sleep score with a possible range from 26 to 130, and a total SDSC raw score 55 or more should be considered as"pathological" 24) . In 32 patients treated with oral desmopressin, 4 achieved FR or R at 4 weeks of treatment, and at 8 weeks, 10 additional patients attained FR or R (Figure-1) . 18 patients who did not respond to desmopressin Table- 2. Before yokukansan treatment, SDSC score was 76.9 (mean value of 18 patients), suggesting that those patients has some sleeping troubles. 10 patients who achieved FR with yokukansan treatment marked statistically lower SDSC score (p = 0.005, Wilcoxon signed-rank test), however the rest 8 patients who had unchanged with yokukansan did not (p = 0.429). Although the pharmacological mechanisms by which yokukansan influences the sleep state of patients with nocturnal enuresis remains to be elucidated, our clinical experience indicates yokukansan has some beneficial effects in improving nocturnal enuresis. Subsequently, we prescribed 141 patients who did not achieve full response with oral desmopressin monotherapy (250 patients; from September 2012 to October 2013) (unpublished data). 56 of 141 patients (39.7%) with the combination treatment with desmopressin and yokukansan achieved full response. We expect yokukansan would be a good candidate for the medication of nocturnal enuresis.
